The Real Cost of Running a Phase 3 Pivotal Breast Cancer Clinical Trial

By Patricio Ledesma, Founder & CEO, Sofpromed

One of the most common questions I receive from biotechnology and oncology sponsors is:

"How much should we budget for a global Phase 3 breast cancer clinical trial?"

After supporting international oncology studies across multiple regions, I can say that many sponsors significantly underestimate the total investment required for a pivotal registration-enabling trial.

In reality, a Phase 3 breast cancer study involving 250 patients across 10 countries can easily require a budget between $45 million and $80 million USD, depending on protocol complexity, imaging requirements, biomarker testing, survival follow-up duration, and monitoring strategy.

In this article, I will provide a realistic budget model for a pivotal breast cancer trial conducted in:

• United States
• Canada
• Australia
• Taiwan
• Singapore
• United Kingdom
• Spain
• France
• Italy
• Poland

For this example, I assume:

Overall Budget Summary

Table 1. Global Trial Budget Overview

Cost Split: CRO Services versus Pass-Through Costs

Sponsors often focus on CRO fees.

In reality, CRO fees are usually a minority of the total investment.

Table 2. Percentage Allocation

Key Takeaway

From my experience, approximately:

• 25-35% of budget goes to CRO services
• 55-65% goes to pass-through costs
• 5-10% should be reserved for contingency

Detailed CRO Full-Service Budget

The CRO budget covers the operational management of the trial.

Table 3. CRO Full-Service Budget

Detailed Pass-Through Budget

Pass-through costs are sponsor expenses paid through the CRO or directly to vendors.

Table 4. Site and Investigator Costs

Table 5. Central Laboratory and Biomarker Costs

Breast cancer trials increasingly depend on biomarker data.

Table 6. Imaging Costs

In oncology, imaging can be one of the largest hidden costs.

Table 7. Regulatory and Insurance Costs

Table 8. Technology and Systems

Table 9. Drug Supply and Logistics

Country-Level Cost Distribution

Not all countries contribute equally to the budget.

Table 10. Estimated Enrollment and Cost by Country

Recruitment Performance

One lesson I have learned after supporting multinational studies is that recruitment performance matters more than nominal site cost.

Many sponsors focus excessively on reducing per-patient costs.

However:

• Slow enrollment creates expensive delays.
• Delays increase CRO staffing expenses.
• Delays prolong vendor contracts.
• Delays extend database lock timelines.
• Delays postpone regulatory submissions.
• Delays shorten patent exclusivity windows.

Countries such as:

• Spain
• Poland
• France
• Italy

often provide an excellent balance between:

• investigator quality
• patient availability
• operational cost
• regulatory predictability

My Top 7 Cost-Reduction Strategies for Pivotal Breast Cancer Trials

Based on my experience managing global clinical development programs, these are the strategies that consistently generate the largest savings.

1. Select Fewer, Higher-Enrolling Sites

A site recruiting 15 patients is much more efficient than three sites recruiting five each.

Reducing site numbers lowers:

• start-up fees
• monitoring visits
• regulatory maintenance
• contracts
• TMF workload

Savings can exceed $1-2 million.

2. Use Risk-Based Monitoring

Following ICH E6(R3) principles, sponsors can reduce monitoring frequency through centralized oversight.

Potential savings:

15-25% of monitoring budget

3. Centralize Biomarker Testing

Avoid local testing whenever possible.

Central laboratories improve:

• consistency
• data quality
• regulatory defensibility

while often lowering overall cost.

4. Prioritize High-Recruiting Countries

The fastest recruiting oncology countries frequently include:

• Spain
• Poland
• France
• United Kingdom

Reducing dependence on slower markets decreases timeline risk.

5. Avoid Protocol Amendments

The most expensive mistake in Phase 3 trials is a major protocol amendment.

A single amendment can cost:

$500,000 to $3 million

depending on scope.

6. Incorporate Adaptive Operational Planning

Early enrollment forecasting allows rapid expansion into reserve countries if recruitment slows.

Proactive planning is almost always less expensive than reactive rescue efforts.

7. Partner with an Experienced Oncology CRO

Experienced oncology teams anticipate:

• RECIST challenges
• imaging review bottlenecks
• biomarker logistics
• safety signal management
• country-specific oncology workflows

This frequently saves more money than selecting the lowest CRO bid.

How Sofpromed Can Support Global Oncology Trials

At Sofpromed, we support biotechnology and pharmaceutical sponsors running international oncology programs through:

• Global project management
• Clinical monitoring
• Medical monitoring
• Pharmacovigilance
• Data management
• Biostatistics
• Medical writing
• Vendor management
• Regulatory affairs
• Quality assurance
• Strategic country selection

For breast cancer studies and other oncology programs, our objective is always the same: maximize recruitment efficiency, maintain exceptional data quality, and reduce unnecessary operational costs without compromising regulatory compliance.

Final Thoughts

For a 250-patient Phase 3 pivotal breast cancer trial conducted across 10 countries over approximately 46 months, sponsors should realistically anticipate a total budget in the range of $60-65 million USD, with approximately 29% allocated to CRO services and 61% allocated to pass-through expenses, plus contingency.

The sponsors that control costs most effectively are not necessarily those negotiating the lowest site fees. 

The most successful sponsors focus on operational efficiency, country selection, protocol quality, centralized oversight, and experienced execution teams. 

Those factors typically have a much greater effect on the final budget than small reductions in individual line items.